We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$923M
Cap. Flow
+$224M
Cap. Flow %
2.14%
Top 10 Hldgs %
34.54%
Holding
153
New
17
Increased
27
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$170M
2
AET
Aetna Inc
AET
+$79.5M
3
UHS icon
Universal Health Services
UHS
+$75.3M
4
KALA icon
KALA BIO
KALA
+$52.2M
5
IMMU
Immunomedics Inc
IMMU
+$50.5M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$185M
2
EW icon
Edwards Lifesciences
EW
+$51.3M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$50.6M
4
INSM icon
Insmed
INSM
+$48M
5
GKOS icon
Glaukos
GKOS
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.18%
2 Financials 2.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBRV
76
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$32.1M 0.31%
15,678
– –
GKOS icon
77
Glaukos
GKOS
$9.3B
$27.6M 0.26%
836,500
-905,200
-52% -$34.4M
ASMB icon
78
Assembly Biosciences
ASMB
$497M
$26.1M 0.25%
62,336
-11,700
-16% -$3.59M
SYBX
79
DELISTED
Synlogic
SYBX
$25M 0.24%
+87,666
New +$17.9M
INCY icon
80
PUT
Incyte
INCY
$25.2B
$23.3M 0.22%
+200,000
New +$25.3M
ICPT
81
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$22.4M 0.21%
386,380
-470,174
-55% -$50.6M
DBVT
82
DBV Technologies
DBVT
$803M
$21.8M 0.21%
51,290
– –
OBSV
83
DELISTED
ObsEva SA Ordinary Shares
OBSV
$21.2M 0.2%
2,605,531
– –
NTRA icon
84
Natera
NTRA
$35.8B
$20.3M 0.19%
1,576,190
+300,000
+24% +$3.33M
EVHC
85
DELISTED
Envision Healthcare Holdings Inc
EVHC
$19.8M 0.19%
440,700
-137,400
-24% -$7.33M
SVA
86
DELISTED
Sinovac Biotech, Ltd
SVA
$18.8M 0.18%
2,667,500
– –
ZLAB icon
87
Zai Lab
ZLAB
$2.07B
$17.8M 0.17%
+658,160
New +$18.4M
NBIX icon
88
Neurocrine Biosciences
NBIX
$18.2B
$17.5M 0.17%
284,841
– –
VNDA icon
89
Vanda Pharmaceuticals
VNDA
$301M
$17.3M 0.17%
967,859
– –
XNCR icon
90
Xencor
XNCR
$1.44B
$17.1M 0.16%
747,244
– –
CTIC
91
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$15.9M 0.15%
5,000,000
– –
NVO
92
Novo Nordisk
NVO
$227B
$15.9M 0.15%
+660,000
New +$14.9M
ADAP
93
DELISTED
Adaptimmune Therapeutics
ADAP
$15.7M 0.15%
1,914,660
– –
SHPG
94
PUT
DELISTED
Shire pic
SHPG
$15.3M 0.15%
+100,000
New +$15.7M
HCA icon
95
HCA Healthcare
HCA
$91.9B
$14.9M 0.14%
187,400
-410,000
-69% -$33M
CHRS icon
96
Coherus Oncology
CHRS
$217M
$14.4M 0.14%
1,079,700
– –
NVTA
97
DELISTED
Invitae Corporation
NVTA
$14.2M 0.14%
1,518,197
+1,061,531
+232% +$10.1M
STDY
98
DELISTED
SteadyMed Ltd
STDY
$14.2M 0.14%
4,246,196
– –
WMGIZ
99
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$13.5M 0.13%
8,713,088
+33,113
+0.4% +$50.6K
ELDN icon
100
Eledon Pharmaceuticals
ELDN
$257M
$13.2M 0.13%
140,951
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2017 Portfolio in Review

As of Q3 2017, OrbiMed held 153 positions worth $10.5B, up 9.7% from $9.54B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q3 2017 filing shows 17 new, 27 increased, 30 reduced and 10 closed positions. Its largest new stake was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M. The largest sale was Humana, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q3 2017 buy was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M.
  • OrbiMed added most to Aetna Inc in Q3 2017, an estimated $79.5M increase.
  • OrbiMed's biggest Q3 2017 reduction was Edwards Lifesciences, cutting an estimated $51.3M.
  • OrbiMed fully exited Humana in Q3 2017, selling an estimated $185M.
  • OrbiMed's ten largest holdings make up 35% of its $10.5B portfolio in Q3 2017.
  • OrbiMed opened 17 new positions and closed 10 in Q3 2017.
  • OrbiMed's portfolio value rose 9.7% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q3 2017, filed 14 Nov 2017.